0QXX.LSE Molecular Partners AG
- Market cap
- GBP 60.4M
- P/E
- 0.8x
- P/B
- -
- ROE
- -91.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0QXX.LSE undervalued?
Graham numberThe Graham number of Molecular Partners AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Molecular Partners AG fundamental analysis
No fundamental analysis for Molecular Partners AG yet.
Molecular Partners AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) …
Full company profileMolecular Partners AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Molecular Partners AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.0M | 20.0M | 10.4M | 20.4M | 9.34M | 9.75M | 190M | 7.04M | 4.97M | - | - |
| Gross Profit | -12.1M | 18.9M | -27.8M | -23.1M | -46.7M | -45.2M | 140M | -40.8M | -42.5M | -2.15M | -1.97M |
| Operating Income | -19.5M | -25.8M | -37.4M | -36.7M | -58.3M | -63.4M | 117M | -61.1M | -61.2M | -55.4M | -54.0M |
| EBITDA | -17.5M | -24.3M | -36.1M | -34.2M | -55.4M | -60.9M | 119M | -59.5M | -51.6M | -53.3M | -52.1M |
| Net Income | -18.6M | -25.4M | -37.0M | -36.3M | -62.8M | -63.8M | 118M | -62.0M | -54.0M | -61.7M | -53.4M |
| EPS | -0.91 | -1.22 | -1.75 | -1.69 | -2.51 | -2.06 | 3.54 | -1.89 | -1.59 | -1.65 | -1.38 |
| Balance Sheet | |||||||||||
| Total Assets | 184M | 144M | 155M | 105M | 188M | 173M | 262M | 198M | 159M | 102M | 75.7M |
| Total Liabilities | 48.3M | 27.7M | 63.5M | 50.8M | 80.3M | 65.4M | 27.1M | 21.9M | 16.9M | 21.8M | 17.2M |
| Shareholders' Equity | 136M | 117M | 91.7M | 54.1M | 107M | 107M | 235M | 176M | 142M | 80.3M | 58.5M |
| Cash & Short-term Investments | 180M | 141M | 99.0M | 95.1M | 174M | 133M | 249M | 187M | 149M | 93.1M | 67.9M |
| Total Debt | - | - | - | 1.28M | 7.22M | 6.04M | 4.85M | 3.65M | 2.44M | 3.64M | 3.04M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.1M | -39.4M | -41.7M | 207K | -28.4M | -90.9M | 119M | -59.0M | -55.0M | -49.5M | -49.5M |
| Capital Expenditure | 1.10M | 500K | 867K | 1.86M | 1.68M | 1.31M | 1.42M | 575K | 705K | 714K | 40.0K |
| Free Cash Flow | -36.2M | -39.9M | -42.6M | -1.66M | -30.1M | -92.2M | 118M | -59.6M | -55.7M | -50.2M | -49.6M |
| Ratios | |||||||||||
| ROE | -13.7% | -21.8% | -40.4% | -67.0% | -58.5% | -59.5% | 50.1% | -35.1% | -38.2% | -76.7% | -91.2% |
| ROA | -10.1% | -17.6% | -23.9% | -34.6% | -33.5% | -36.9% | 44.9% | -31.2% | -34.1% | -60.4% | -70.5% |
| Net Profit Margin | -80.8% | -127.0% | -357.7% | -178.0% | -671.7% | -653.9% | 62.2% | -880.7% | -1,087.4% | - | - |
| Debt to Equity | - | - | - | 0.02x | 0.07x | 0.06x | 0.02x | 0.02x | 0.02x | 0.05x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Molecular Partners AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | GBP 1.57M | 0.05 | 1.3% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Molecular Partners AG
- Insiders 8.47%
- Institutions 43.82%
- Public & others 47.71%
- Shares outstanding 21.2M
- Free float 20.4M
Molecular Partners AG company profile
- Company name
- Molecular Partners AG
- Ticker
- 0QXX.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 134
- Fiscal year end
- December
- Address
- Wagistrasse 14, Schlieren, Switzerland, 8952
- Phone
- 41 44 755 77 00
- Website
- molecularpartners.com
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Molecular Partners AG management
10- Dr. Patrick Amstutz Ph.D.Co-Founder, CEO, Member of Management Board & Director · born 1975
- Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive VP of Projects & Member of Management Board · born 1972
- Mr. Robert HendriksSenior VP of Finance & Member of Management Board
- Mr. Alexander ZurcherCOO & Member of Management Board · born 1975
- Ms. Renate GloggnerExecutive VP of People & Community and Member of Management Board · born 1970
- Dr. Philippe Legenne M.B.A., M.D.Chief Medical Officer & Member of the Management Board · born 1966
- Mr. Martin Steegmaier Ph.D.Chief Scientific Officer & Member of the Management Board · born 1966
- Mr. Michael PitznerExecutive VP of Partnering & General Counsel
- Dr. Pamela A. Trail Ph.D.Strategic Consultant · born 1956
- Mr. Daniel Steiner Ph.D.Senior Vice President of Targeted Radio Therapeutics